Poor
Needs Revision
Patient Risk:
Moderate
Summary
Several safety/efficacy claims are unsupported by the provided label excerpts (notably alcohol-related bleeding/liver/kidney risk and multiple downstream symptom/cause assertions). Bleeding risk with concomitant antithrombotic agents is supported, but many other mechanistic and clinical-outcome links are not found in the provided label text.
Category Scores
Accurate Statements
Vascepa can increase the risk of bleeding.
Supported by Label 5.3 Bleeding (increased bleeding; serious bleeding events higher vs placebo).
The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin.
Supported by Label 5.3 Bleeding (incidence greater with concomitant antithrombotic medications).
Unsupported Statements
Vascepa (icosapent ethyl) is a prescription medication used to treat high triglycerides.
The provided label excerpt specifies indications as adjunct to maximally tolerated statin therapy to reduce risk of CV events in specific adult populations with elevated triglycerides, and as adjunct to diet to reduce TG levels in adults with severe hypertriglyceridemia. The broad statement 'used to treat high triglycerides' omits the label-specific indication context.
Adding alcohol to Vascepa can further increase the risk of bleeding.
No alcohol-specific bleeding risk guidance is present in the provided excerpts.
Mixing Vascepa and alcohol can increase the likelihood of bleeding because both substances can thin the blood.
No alcohol-specific guidance and no 'both substances thin the blood' rationale is provided in the label excerpts.
Bleeding can lead to internal bleeding.
The provided excerpts discuss bleeding events but do not describe internal bleeding progression.
Bleeding can lead to hemorrhages.
The provided excerpts discuss bleeding events/serious bleeding but do not state progression to 'hemorrhages.'
Bleeding can lead to anemia.
No label excerpt states bleeding leads to anemia.
Vascepa can cause liver damage.
The provided excerpts include hepatic impairment monitoring (ALT/AST monitoring) but do not state that VASCEPA causes liver damage.
Vascepa-associated liver damage is particularly associated with high doses or extended periods.
No dose/duration relationship for liver damage is provided in the excerpts.
Combining Vascepa with alcohol can increase the risk of liver damage.
No alcohol-specific liver risk guidance is provided in the excerpts.
Vascepa-associated liver damage can lead to jaundice.
No label excerpt lists jaundice as a consequence of VASCEPA liver damage.
Vascepa-associated liver damage can lead to fatigue.
No label excerpt ties liver damage to fatigue.
Vascepa-associated liver damage can lead to abdominal pain.
No label excerpt ties liver damage to abdominal pain.
Vascepa-associated liver damage can lead to nausea and vomiting.
No label excerpt ties liver damage to nausea/vomiting.
Vascepa can cause kidney damage.
The provided excerpts contain no kidney damage statement; they only address hepatic impairment monitoring.
Vascepa-associated kidney damage is particularly increased in patients with pre-existing kidney disease.
No kidney-risk excerpt or CKD-specific statement is provided.
Combining Vascepa with alcohol can increase the risk of kidney damage.
No alcohol-specific kidney risk guidance is provided in the excerpts.
Kidney damage can lead to kidney failure.
No label excerpt states kidney damage or progression to kidney failure.
Kidney damage can lead to fluid buildup.
No label excerpt states this progression.
Kidney damage can lead to high blood pressure.
No label excerpt states this progression.
Kidney damage can lead to fatigue.
No label excerpt states this progression.
Vascepa can interact with other medications including cholesterol-lowering medications.
The provided drug-interaction excerpt provided (7.1) discusses anticoagulants/antiplatelet agents and bleeding-time studies; it does not mention cholesterol-lowering medications as interaction examples.
Vascepa can interact with other medications including antihistamines.
No such interaction is provided in the excerpts.
Combining Vascepa with alcohol can increase the risk of interactions with other medications.
No alcohol-related interaction guidance is provided in the excerpts.
Interactions with other medications can lead to an increased risk of bleeding.
Bleeding risk with concomitant anticoagulants/antiplatelet agents is supported, but the generic framing 'interactions with other medications' is broader than the excerpt.
Interactions with other medications can lead to an increased risk of liver damage.
No liver-damage interaction statement is provided in the excerpts.
Interactions with other medications can lead to an increased risk of kidney damage.
No kidney-damage interaction statement is provided in the excerpts.
Interactions with other medications can lead to an increased risk of allergic reactions.
The provided excerpts address potential allergic reactions in fish/shellfish allergy, not medication interactions causing allergic reactions.
It is best to avoid mixing Vascepa and alcohol altogether.
No alcohol-avoidance guidance is provided in the excerpts.
Mixing Vascepa and alcohol can increase the risk of adverse effects including bleeding, liver damage, kidney damage, and interactions with other medications.
Alcohol-specific adverse effect guidance (especially liver/kidney damage) is not present in the provided excerpts.
Mixing Vascepa and alcohol can increase the risk of adverse effects.
No general alcohol-adverse effect guidance is present in the excerpts.
The guidance states that it is best to avoid mixing Vascepa and alcohol altogether, including a glass of wine.
No alcohol guidance (including wine) is present in the provided excerpts.
It is stated that Vascepa should not be taken with a beer.
No beer-specific or alcohol-specific wording is present in the provided excerpts.
The guidance states that a doctor may prescribe Vascepa with caution in people with a history of liver disease.
The provided hepatic impairment excerpt states ALT/AST monitoring in hepatic impairment; it does not specify 'history of liver disease' or 'doctor may prescribe with caution' wording.
The guidance states to consult a doctor before taking Vascepa with other medications due to interactions.
No explicit consult-language for 'other medications' beyond monitoring for bleeding with concomitant anticoagulants/antiplatelet agents is provided in the excerpts.
Signs of liver damage can include jaundice.
No signs/symptom list for liver damage is provided in the excerpts.
Signs of liver damage can include fatigue.
No signs/symptom list for liver damage is provided in the excerpts.
Signs of liver damage can include abdominal pain.
No signs/symptom list for liver damage is provided in the excerpts.
Signs of liver damage can include nausea and vomiting.
No signs/symptom list for liver damage is provided in the excerpts.
Contradictions
Important Omissions
Bleeding risk increase is specifically described with concomitant antithrombotic medications (aspirin, clopidogrel, warfarin) and requires monitoring for bleeding; the claim set does not accurately constrain increased bleeding to those concomitant antithrombotic agents.
Importance:
Moderate
No mention that VASCEPA is indicated as adjunct to maximally tolerated statin therapy to reduce risk of specific CV events in adults with elevated triglycerides (≥150 mg/dL) with established CVD or diabetes plus risk factors; and as adjunct to diet to reduce TG levels in adults with severe (≥500 mg/dL) hypertriglyceridemia.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported alcohol-related claims and several unlabelled organ-damage/progression assertions (liver/kidney damage and downstream outcomes) may mislead patients or clinicians. However, the core bleeding-risk statement with concomitant antithrombotic agents is supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Multiple claims are not supported by the provided FDA label excerpts, especially alcohol-related bleeding/liver/kidney risk, mechanistic explanations (e.g., blood thinning), and downstream symptom/outcome lists.
Suggested Improvement
Limit claims to what the provided label excerpts support: bleeding risk increased with concomitant antithrombotic medications; monitor for bleeding with anticoagulants/antiplatelet agents. Use label-specific indication wording (CV risk reduction as adjunct to maximally tolerated statin; TG reduction as adjunct to diet in severe hypertriglyceridemia). Remove alcohol and kidney/liver damage causation/progression claims unless directly supported by the actual label sections.